<DOC>
	<DOCNO>NCT03004768</DOCNO>
	<brief_summary>An oral dose healthy subject obtain information absorption , metabolism , excretion ( AME ) BMS-986165</brief_summary>
	<brief_title>Pharmacokinetics Metabolism 14CBMS-986165 Healthy Male Participants</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed Informed Consent Target population : Healthy male clinically significant deviation normal medical history , physical examination , vital sign , electrocardiogram ( ECGs ) , physical measurement , clinical laboratory test Body weight least 50 kilogram ( 110 pound ) ; body mass index ( BMI ) 18 32 kg/m2 . No evidence acute infection significant problem determine review chest xray , medical history , physical examination History chronic acute illness include active TB last 3 year , recent infection , gastrointestinal disease , smoke within less 6 month prior dose , alcohol abuse , inability tolerate oral medication , inability venipunctured . Vaccination plan vaccination live vaccine 12 week prior first dose study drug , course study Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , electrocardiogram , clinical laboratory determination beyond consistent target population . Participant great Grade 2 acne . Participated radiolabeled drug study within previous 12 month ; clinically significant diagnostic therapeutic radiation exposure within previous 12 month ; current employment job require radiation exposure monitoring .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>